SCHEMBL2255149

SCHEMBL2255149

Nc1ccc(N2CCS(O)(O)CC2)c(F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.58
ALDH1A1 P00352 8/20 0.58
GFER P55789 3/20 0.58
LMNA P02545 1/20 0.58
MAPK1 P28482 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
KDM4E B2RXH2 3/20 0.41
RAD52 P43351 2/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 2/20 0.41
THRB P10828 2/20 0.41
KMT2A Q03164 2/20 0.41
ALOX15 P16050 1/20 0.41
YWHAG P61981 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GAA P10253 4/20 0.40
NR4A1 P22736 1/20 0.40
PTK2B Q14289 1/20 0.40
HTT P42858 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17265648 0.84 ALDH1A1 (0.77) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL2255157 0.83 ALDH1A1 (0.58) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL30199085 0.83 ALDH1A1 (0.58) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL7038110 0.80 ALDH1A1 (0.67) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL3442442 0.80 ALDH1A1 (0.67) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL16824888 0.80 MAPT (0.41) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL1809535 0.80 ALDH1A1 (0.65) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL274394 0.80 MAPT (0.53) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL29520597 0.79 ALDH1A1 (0.66) MAPTALDH1A1GFERLMNAMAPK1
SCHEMBL159044 0.79 ALDH1A1 (0.66) MAPTALDH1A1GFERLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2875001-B1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS SUNSHINE LAKE PHARMA CO LTD (CN) 2019-01-09 EP disclosed
US-9434695-B2 Nitrogenous heterocyclic derivatives and their application in drugs SUNSHINE LAKE PHARMA CO., LTD (CN) 2016-09-06 US disclosed
EP-2875001-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS Sunshine Lake Pharma Co., Ltd. (CN) 2015-05-27 EP disclosed
US-20150087639-A1 Nitrogenous Heterocyclic Derivatives And Their Application In Drugs SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-26 US disclosed
WO-2014012360-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-01-23 WO disclosed
US-20110190280-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-08-04 US disclosed
EP-2197876-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS Glaxosmithkline LLC (US) 2010-06-23 EP disclosed
WO-2009032667-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190280-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 MAPT 1402/4885ALDH1A1 3014/4885GFER 4646/4885
US-20150087639-A1 Nitrogenous Heterocyclic Derivatives And Their Application In Drugs TNNC1, TNNI3, IAPP MAPT 623/4885ALDH1A1 1530/4885GFER 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.